<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03999086</url>
  </required_header>
  <id_info>
    <org_study_id>17-006702</org_study_id>
    <nct_id>NCT03999086</nct_id>
  </id_info>
  <brief_title>Thromboelastography-Guided Fluid Management in Spinal Surgery</brief_title>
  <official_title>Thromboelastography-guided Fluid Management in Spinal Surgery: A Prospective Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Researchers are trying to evaluate whether using a blood test called thromboelastogram
      (TEG) to manage patients undergoing multi-level spinal fusion surgery will reduce
      complications after surgery compared with the standard practices.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-level instrumented spinal fusions represent an important treatment modality for
      degenerative scoliosis and sagittal malalignment. These surgeries remain a significant
      physiologic burden with high blood loss and long operative times. Thromboelastography
      provides a quantitative measure for blood product transfusion surrounding procedures. We aim
      to utilize thromboelastography to guide transfusions for multi-level spinal instrumentation.
      This two-arm, randomized, non-blinded prospective analysis will clarify reduced transfusion
      requirements for TEG-arm compared to non-TEG arm. We will also evaluate postoperative
      outcomes at the 1 year time-point.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated Blood Loss</measure>
    <time_frame>post operative approximately 1 day</time_frame>
    <description>Amount of blood loss measured in units of cc(mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of transfused packed red blood cells</measure>
    <time_frame>post operative approximately 1 day</time_frame>
    <description>Amount of transfused packed red blood cells measured in units of cc(mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>One year</time_frame>
    <description>Number of adverse events reported</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Spinal Fusion</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Traditional evaluation/standard-of-care evaluation of patients undergoing multi-level spinal fusion surgery. These patients will receive point-of-care laboratory testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <description>Utilization of TEG for decision-making regarding intra-operative transfusion in major spinal reconstruction surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intervention</intervention_name>
    <description>We will utilize thromboelastography to discern when to transfuse blood products in the setting of multi-level spinal fusion</description>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>Thromboelastography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>Laboratory analysis to guide transfusion</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Point of care testing</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of Mayo Clinic receiving a multi-level spinal fusion surgery.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients undergoing elective multi-level spinal fusion for sagittal malalignment,
             multi-level spondylolisthesis, multi-level lumbar spinal stenosis, and adult
             degenerative scoliosis with ages between 18-89

        Exclusion Criteria:

          -  patients with tumors, infection, or trauma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamal McClendon, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sejal R Patel</last_name>
    <phone>480-301-8260</phone>
    <email>Patel.Sejal@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sejal R Patel</last_name>
      <phone>480-301-8260</phone>
      <email>Patel.Sejal@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jamal McClendon, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>June 25, 2019</last_update_submitted>
  <last_update_submitted_qc>June 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Jamal McClendon, Jr.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

